Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein - PubMed (original) (raw)
Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein
D M Bitar et al. Cell Immunol. 1988.
Abstract
The oral administration of myelin basic protein (MBP) to Lewis rats prior to an encephalitogenic challenge resulted in total inhibition or a significant delay in the onset of experimental autoimmune encephalomyelitis (EAE). In vitro lymphocyte proliferative responses to MBP were significantly decreased in MBP-fed rats when compared with vehicle-fed controls. Suppression of EAE and in vitro proliferative responses to MBP were observed to be antigen specific, since oral feeding of a control protein exerted no suppressive effect. Moreover, the specificity of MBP-induced oral tolerance was shown to be species specific, since feeding guinea pig MBP (GPMBP) or human MBP (HuMBP) induced protection only against a GPMBP or HuMBP challenge, respectively. Conversely, Lewis rats could not be orally tolerized to the self antigen rat MBP.
Similar articles
- Dose-dependent mechanisms relate to nasal tolerance induction and protection against experimental autoimmune encephalomyelitis in Lewis rats.
Li HL, Liu JQ, Bai XF, vn der Meide PH, Link H. Li HL, et al. Immunology. 1998 Jul;94(3):431-7. doi: 10.1046/j.1365-2567.1998.00526.x. Immunology. 1998. PMID: 9767428 Free PMC article. - Orally administered myelin basic protein in neonates primes for immune responses and enhances experimental autoimmune encephalomyelitis in adult animals.
Miller A, Lider O, Abramsky O, Weiner HL. Miller A, et al. Eur J Immunol. 1994 May;24(5):1026-32. doi: 10.1002/eji.1830240503. Eur J Immunol. 1994. PMID: 7514126 - Inhibition of experimental autoimmune encephalomyelitis in Lewis rats by nasal administration of encephalitogenic MBP peptides: synergistic effects of MBP 68-86 and 87-99.
Liu JQ, Bai XF, Shi FD, Xiao BG, Li HL, Levi M, Mustafa M, Wahren B, Link H. Liu JQ, et al. Int Immunol. 1998 Aug;10(8):1139-48. doi: 10.1093/intimm/10.8.1139. Int Immunol. 1998. PMID: 9723700 - Treatment of autoimmune disease by oral tolerance to autoantigens.
Whitacre CC, Gienapp IE, Meyer A, Cox KL, Javed N. Whitacre CC, et al. Clin Immunol Immunopathol. 1996 Sep;80(3 Pt 2):S31-9. doi: 10.1006/clin.1996.0139. Clin Immunol Immunopathol. 1996. PMID: 8811061 Review. - Oral tolerance in experimental autoimmune encephalomyelitis.
Whitacre CC, Gienapp IE, Meyer A, Cox KL, Javed N. Whitacre CC, et al. Ann N Y Acad Sci. 1996 Feb 13;778:217-27. doi: 10.1111/j.1749-6632.1996.tb21130.x. Ann N Y Acad Sci. 1996. PMID: 8610975 Review.
Cited by
- Immune modulating peptides for the treatment and suppression of multiple sclerosis.
Badawi AH, Siahaan TJ. Badawi AH, et al. Clin Immunol. 2012 Aug;144(2):127-38. doi: 10.1016/j.clim.2012.05.010. Epub 2012 Jun 5. Clin Immunol. 2012. PMID: 22722227 Free PMC article. Review. - Oral Tolerance Induction in Experimental Autoimmune Encephalomyelitis with Candida utilis Expressing the Immunogenic MOG35-55 Peptide.
Buerth C, Mausberg AK, Heininger MK, Hartung HP, Kieseier BC, Ernst JF. Buerth C, et al. PLoS One. 2016 May 9;11(5):e0155082. doi: 10.1371/journal.pone.0155082. eCollection 2016. PLoS One. 2016. PMID: 27159446 Free PMC article. - T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.
O'Brien K, Gran B, Rostami A. O'Brien K, et al. Immunotherapy. 2010 Jan;2(1):99-115. doi: 10.2217/imt.09.61. Immunotherapy. 2010. PMID: 20231863 Free PMC article. Review. - Oral tolerance.
Faria AM, Weiner HL. Faria AM, et al. Immunol Rev. 2005 Aug;206:232-59. doi: 10.1111/j.0105-2896.2005.00280.x. Immunol Rev. 2005. PMID: 16048553 Free PMC article. Review. - Oral tolerance.
Wu HY, Weiner HL. Wu HY, et al. Immunol Res. 2003;28(3):265-84. doi: 10.1385/IR:28:3:265. Immunol Res. 2003. PMID: 14713719 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous